CD8A and ovarian cancer: Inhibition of NAC1 reduced the recruitment and immunosuppressive function of MDSCs in the TME, led to significant increases of cytotoxic tumor infiltrating CD8+ T cells, potentiated anti-PD-1 therapy, and suppressed tumor progression in ovarian cancer (70).